Numab Therapeutics is developing multi-specific antibody-based immunotherapies for inflammation and cancer. Reproducible plug-and-play therapeutic design process using proprietary platforms λ-Cap™ and MATCH™ puts Numab in a unique position to overcome historical drug discovery barriers and build a pipeline of first-in-class and best-in-class medicines aimed to maximize patient benefits. Our lead candidate NM26, a unique multi-specific targeting IL-4/13 and IL-31 for best-in-class efficacy, is developed with a vision of delivering a lifelong cure to patients suffering from atopic dermatitis (AD) and other potential indications.
View Top Employees from Numab Therapeutics AGWebsite | http://www.numab.com |
Revenue | $7 million |
Funding | $132.7 million |
Employees | 77 (56 on RocketReach) |
Founded | 2011 |
Address | 34 Einsiedlerstrasse, Wädenswil, Zurich 8820, CH |
Phone | +41 44 533 04 71 |
Technologies |
JavaScript,
HTML,
Google Analytics
+5 more
(view full list)
|
Industry | Biotechnology Research, Medical Devices & Equipment, Biotechnology, Manufacturing, Science and Engineering, Therapeutics, Health Care |
Web Rank | 9 Million |
Keywords | Numab Therapeutics Ag -, Numab Innovation |
Competitors | Complix N.V., HARBOUR BIOMED, PDS Biotechnology, Paranta Biosciences Ltd, Symic Bio |
SIC | SIC Code 873 Companies, SIC Code 87 Companies |
NAICS | NAICS Code 541 Companies, NAICS Code 33 Companies, NAICS Code 54 Companies |
Looking for a particular Numab Therapeutics AG employee's phone or email?
The Numab Therapeutics AG annual revenue was $7 million in 2024.
Sebastian Meyer is the COO of Numab Therapeutics AG.
56 people are employed at Numab Therapeutics AG.
Numab Therapeutics AG is based in Wädenswil, Zurich.
The NAICS codes for Numab Therapeutics AG are [541, 33, 54].
The SIC codes for Numab Therapeutics AG are [873, 87].